Clinical Trial Update: Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AL-15469A 0.5% / AL-6515 0.3% ophthalmic suspension for bacterial conjunctivitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• AL-15469A ophthalmic suspension
• AL-6515 ophthalmic suspension

Snippet

Sponsor: Alcon Research | Conditions: Bacterial Conjunctivitis | Phase 2 | Status: WITHDRAWN